Similar demographics, clinical characteristics, and treatment patterns in German claims study

Despite different administration methods and mechanisms of action, similar annualised relapse rates (ARR) and treatment persistence were observed in patients with relapsing multiple sclerosis (MS) on disease-modifying therapy (DMT). These were the results of a retrospective study using data from a German real-world insurance claims database. Glatiramer acetate has been licensed as an injectable treatment for relapsing MS in Europe for over 20 years; follow-on glatiramer acetate received approval in 2016. Various oral DMTs have become available on the European market for the treatment of relapsing MS, including dimethyl fumarate and teriflunomide. However, overall real-world data on treatment patterns and associated health outcomes in patients with relapsing MS using these DMTs are limited. The retrospective database analysis presented by Prof. Tjalf Ziemssen (University Hospital Carl Gustav Carus, Germany) evaluated...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 16 December, 202016 December, 2020